Randomized, Phase I, Placebo-controlled, Dose-Ranging, study to evaluate the Safety, Tolerability and Immunogenicity of the candidate HGCO19 (COVID-19 vaccine) in healthy adult subjects - Randomized, Phase I, Placebo-controlled, Dose-Ranging, study to evaluate the Safety, Tolerability and Immunogenicity of the candidate HGCO19 (COVID-19 vaccine) in healthy adult subjects

Gennova Biopharmaceuticals Limited0 个研究点目标入组 82 人开始时间: 待定最近更新: 2023年10月16日

试验速览

阶段: 1 期
状态: 已完成
发起方: Gennova Biopharmaceuticals Limited
入组人数: 82

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional

入排标准

入选标准

•1. Male and female subjects aged between 18 to 70 years(both inclusive) at randomization. 2. Healthy as judged by medical history, physical and other examination or investigations and in the clinical opinion of the Investigator. 3. Subject should be capable and willing to give voluntary written informed consent prior to inclusion in the study. 4. Able to comprehend and comply with study requirements and procedures and be able and willing to complete subject diary. 5. Negative / Non-reactive for antibodies against SARS-CoV-2. 6. Negative / Non-reactive RT-PCR screening of nasopharyngeal swabs/suitable sample for SARS CoV-2 within 72 hours prior vaccination. 7. Male subjects who are sexually active or married and female subjects who are sexually active or married and are of child bearing potential should be willing to follow effective birth control methods for duration of the study. Note: Birth control methods include vasectomised subject/partner; or any 2 of the following methods: intrauterine device; oral, transdermal, injected, or implanted contraceptive; condoms; occlusive cap (diaphragm or cervical vault caps); spermicidal foam/gel/cream, etc. OR Exception to the above are male subjects who are infertile (post vasectomy with documented azoospermia or bilateral orchidectomy) and female subjects who are of non-childbearing potential [who are surgically sterile (hysterectomy, bilateral tubal ligation or bilateral salpingo-oophorectomy) or postmenopausal subjects with amenorrhea for at least 2 years]

排除标准

•1. Subject with a medical history of COVID-19 infection or who has received vaccine to prevent COVID-19 infection.
•2. Subjects with a BMI > 30 kg/m2
•3. Protocol defined laboratory assessments outside the range/limit defined in Appendix 2. Any other laboratory value if = Grade 2 as per DAIDs criteria.
•Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, corrected version 2.1, July 2017, of the US National Institutes of Health
•4. Any illness or any other current or pre-existing health condition (e.g. any major pulmonary, cardiovascular, renal, neurological, metabolic, gastro-intestinal, hepato-biliary, haematological functional abnormality, mental or physical disability, blood dyscrasia, major congenital defects, etc.) which in the opinion of the Investigator may affect the safety of the subject or the study endpoints.
•5. Individuals currently working in occupations with high risk of exposure to SARS-CoV-2 (e.g. healthcare worker in direct care of COVID-19 patients, front line workers in COVID 19 hotspots / outbreak areas).
•6. History of allergic/hypersensitivity reactions or anaphylaxis to any vaccine or components of study vaccine.
•7. Subject has any acute illness (moderate or severe) at the time of vaccination and/or fever (oral temperature =38°C or =100.4 °F) within 48 hours prior to vaccination.
•8. History of cancer, organ transplant, any other clinically significant immunosuppressive condition or autoimmune disease.
•9. Subject has uncontrolled chronic disease including asthma, diabetes (HbA1c of >9%), hypertension (Systolic Blood pressure of >160 mm of Hg and/ or Diastolic Blood Pressure of >100 mm of Hg), thyroid disorder as assessed by the Investigator.
•10. Subjects who are pregnant or breast feeding or willingness/intention to become pregnant during the study.
•11. Prior major surgery or any radiation therapy within 4 weeks of Screening visit.
•12. Positive serologic test for HIV 1 and 2, HBsAg or HCV.
•13. Current (within 14 days prior to Screening visit) or anticipated concomitant immune modifying or immunosuppressive therapy (excluding inhaled, topical skin or eye drop-containing corticosteroids, low-dose methotrexate, or corticosteroids at a dose less than 20 mg/day).
•14. Planned or actual receipt of any vaccine other than the study intervention within 30 days before and after each study vaccination.
•15. Eczema or other significant skin lesion or infection at the site of vaccination.
•16. Administration of blood, blood products and/or plasma derivatives or any immunoglobulin preparation 90 days prior to screening visit.
•17. Bleeding diathesis or condition associated with prolonged bleeding.
•18. Participating in another clinical trial within 30 days prior to Screening visit or planning to participate in another clinical trial during the study duration or planning to migrate.
•19. Any other condition which in the opinion of the Investigator may affect subject’s safety or participation.

研究者

发起方

Gennova Biopharmaceuticals Limited

相似试验

进行中（未招募）

1 期

EUCTR2014-000428-12-FRovartis Pharma Services AG90

进行中（未招募）

1 期

EUCTR2014-000428-12-NLovartis Pharma Services AG42

进行中（未招募）

1 期

EUCTR2014-000428-12-ITOVARTIS FARMA S.P.A.10

进行中（未招募）

不适用

Study for patients with relapsed, refractory, incurable teratoma with recent progression. The study is randomized (the patient may receive the investigational drug or placebo) and it is blinded (the patient and the study doctor will not know what drug the patient receives).relapsed, refractory, incurable teratomaMedDRA version: 18.0Level: PTClassification code 10043276Term: TeratomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

EUCTR2014-000428-12-DKovartis Pharma Services AG42

已完成

2 期

A randomized, blinded, placebo-controlled, phase II trial of LEE011 in patients with relapsed, refractory, incurable teratoma with recent progressioTeratomaorganoid tumor10027656

NL-OMON41774ovartis6